Valuation: Genmab

Market Cap 135B 20.32B 18.05B 16.85B 15.36B 28.96B 1,953B 29.23B 204B 79.01B 998B 76.28B 74.63B 3,204B P/E 2026 *
28.8x
P/E 2027 * 20.5x
Enterprise Value 154B 23.22B 20.63B 19.25B 17.55B 33.1B 2,232B 33.41B 233B 90.29B 1,141B 87.17B 85.28B 3,662B EV / Sales 2026 *
5.3x
EV / Sales 2027 * 4.32x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
+85.46%+4.14% - - 20.81B
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.93%-4.34%+26.58%+33.40% 42.91B
+0.27%+0.48%+350.68%+687.01% 44.13B
-1.46%-2.18%+2.26%+97.74% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+1.14%-6.81%-28.14%+332.81% 23.71B
Average -0.25%-0.64%+52.17%+158.24% 43.6B
Weighted average by Cap. +0.02%-0.40%+57.28%+149.85%

Financials

2026 *2027 *
Net sales 29.07B 4.38B 3.89B 3.63B 3.31B 6.24B 421B 6.3B 43.95B 17.03B 215B 16.44B 16.08B 691B 33.76B 5.09B 4.52B 4.22B 3.84B 7.25B 489B 7.32B 51.04B 19.78B 250B 19.09B 18.68B 802B
Net income 4.98B 751M 667M 622M 567M 1.07B 72.16B 1.08B 7.53B 2.92B 36.89B 2.82B 2.76B 118B 7.18B 1.08B 961M 897M 817M 1.54B 104B 1.56B 10.85B 4.2B 53.14B 4.06B 3.97B 171B
Net Debt 19.25B 2.9B 2.58B 2.41B 2.19B 4.13B 279B 4.17B 29.11B 11.28B 143B 10.89B 10.65B 457B 11.09B 1.67B 1.48B 1.39B 1.26B 2.38B 161B 2.4B 16.77B 6.5B 82.13B 6.27B 6.14B 264B
Logo Genmab
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A